Summit Therapeutics (SMMT) Leases (2019 - 2025)
Summit Therapeutics' Leases history spans 7 years, with the latest figure at $5.4 million for Q3 2025.
- For Q3 2025, Leases fell 32.05% year-over-year to $5.4 million; the TTM value through Sep 2025 reached $5.4 million, down 32.05%, while the annual FY2024 figure was $7.1 million, 21.93% up from the prior year.
- Leases reached $5.4 million in Q3 2025 per SMMT's latest filing, down from $5.6 million in the prior quarter.
- In the past five years, Leases ranged from a high of $9.4 million in Q1 2024 to a low of $1.5 million in Q1 2021.
- Average Leases over 5 years is $5.0 million, with a median of $5.4 million recorded in 2025.
- Peak YoY movement for Leases: surged 403.61% in 2021, then crashed 36.3% in 2025.
- A 5-year view of Leases shows it stood at $2.8 million in 2021, then skyrocketed by 49.64% to $4.2 million in 2022, then surged by 40.34% to $5.9 million in 2023, then rose by 21.93% to $7.1 million in 2024, then decreased by 24.13% to $5.4 million in 2025.
- Per Business Quant, the three most recent readings for SMMT's Leases are $5.4 million (Q3 2025), $5.6 million (Q2 2025), and $6.4 million (Q1 2025).